Last reviewed · How we verify
Toripalimab injection
Toripalimab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.
Toripalimab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells. Used for Melanoma, Non-small cell lung cancer, Nasopharyngeal carcinoma.
At a glance
| Generic name | Toripalimab injection |
|---|---|
| Also known as | JS001, PD-1 inhibitor, Toripalimab, EBV-DNA positive |
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Toripalimab binds to programmed death receptor 1 (PD-1) on T cells, preventing interaction with PD-L1 and PD-L2 ligands expressed by tumor cells and immune cells. This blockade reverses T cell exhaustion and restores anti-tumor immune responses. It is a humanized IgG4 monoclonal antibody designed to enhance endogenous anti-tumor immunity.
Approved indications
- Melanoma
- Non-small cell lung cancer
- Nasopharyngeal carcinoma
- Esophageal squamous cell carcinoma
Common side effects
- Fatigue
- Decreased appetite
- Nausea
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Infusion-related reactions
Key clinical trials
- Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors (PHASE2)
- Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors (PHASE1)
- Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PHASE3)
- A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma (PHASE3)
- A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer (PHASE1, PHASE2)
- A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. (PHASE1, PHASE2)
- A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors (PHASE1, PHASE2)
- PDT For Induction Therapy For Head And Neck Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |